lower schreef op 19 maart 2015 09:21:
Einde van het jaar kas leeg denk ik....
Operating costs, nieuwe commissarissen, investeringen in eiwit-projecten, eigen sales force in aantal EU landen.
GOING CONCERN
Pharming’s 2014 financial statements have been drawn up on the basis of a going concern assumption.
The 2014 year- end cash balance of
€34.4 million is expected to fund the Company for at least one year from the date of the report. The receipts from commercial supply of product to our partners in the EU, Israel and the US and proceeds from direct sales in Aust
ria, Germany and the Netherlands will further increase our financial reserves.
Pharming has a history of operating losses and anticipates that it will
continue to incur losses until such quantities of Ruconest are sold, that the proceeds to Pharming from such sales have become sufficient to off - set our losses.
Presently, no assurance can be given both on the timing and size of future profits and
if profitability can ever be achieved on this basis.
In addition, to the extent the Company needs to raise cap
ital by issuing additional shares,
shareholders’ equity
interests will be diluted.
Scary.....